Bioorganic and Medicinal Chemistry Letters p. 4805 - 4811 (2017)
Update date:2022-08-03
Topics:
Storer, R. Ian
Pike, Andy
Swain, Nigel A.
Alexandrou, Aristos J.
Bechle, Bruce M.
Blakemore, David C.
Brown, Alan D.
Castle, Neil A.
Corbett, Matthew S.
Flanagan, Neil J.
Fengas, David
Johnson, M. Scott
Jones, Lyn H.
Marron, Brian E.
Payne, C. Elizabeth
Printzenhoff, David
Rawson, David J.
Rose, Colin R.
Ryckmans, Thomas
Sun, Jianmin
Theile, Jonathan W.
Torella, Rubben
Tseng, Elaine
Warmus, Joseph S.
The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein–ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation.
View MoreNingbo Tide Imp. & Exp. Co., Ltd.
Contact:+86-571-8993 7933; +86-571-8993 6453
Address:7/F Anno Domini Building, Tower South, 8 Qiu Shi Road,Hangzhou,China.
Contact:+44 (0)2036089360-31
Address:Chanceryhouse,Chancery Lan
Shijiazhuang Frontierchem Co., Ltd.
Contact:+86-311-89271196
Address:4-4-202 No.15 Biandian Street,Shijiazhuang
Contact:86-607-68073220
Address:1 ave na road jiahua st
Shenzhen JYMed Technology Co.,Ltd.
website:http://www.jymedtech.com
Contact:+86-755-26612112
Address:1#8,9/F, Biomedicine innovation Industrial Park, No.14, Jinhui Road, Pingshan Sistrict, Shenzhen, China
Doi:10.1016/j.ejmech.2017.05.037
(2017)Doi:10.1039/jr9370000286
(1937)Doi:10.1002/mrc.4295
(2015)Doi:10.1021/ja0545517
(2005)Doi:10.1016/S0040-4039(00)86271-1
(1983)Doi:10.1016/j.tetasy.2005.11.004
(2005)